Group 1 - The company is actively embracing AI technology through self-research and partnerships with leading firms like Alibaba Cloud and Tencent Cloud, developing AI applications for various scenarios to accelerate digital transformation in business and management [1][2] - AI applications include smart logistics, integrated Chinese and Western medicine diagnosis, medical devices, and intelligent office solutions, significantly improving operational efficiency and patient experience across different platforms [1][2] - The AI logistics project "Goods to Person" has enhanced overall efficiency by 10% through the application of intelligent scheduling algorithms across the entire lifecycle of order grouping, product storage, and dispatch [1] Group 2 - The company has implemented an internal office system and a digital assistant "Zhi Jiu Ge" integrated with DeepSeek, resulting in a 38% increase in work efficiency [2] - As of July 2025, the company has over 2,400 clinic membership stores and aims to establish a network of 10,000 clinics within three years, focusing on a business model that integrates medical services with supply chain management [2] - The company has introduced over 260 new products in the first half of the year, enhancing the product structure in clinics through partnerships with various upstream manufacturers [2] Group 3 - The company has launched the "Jiu Yi SaaS Clinic Manager" system, enabling rapid operations such as 3-second record creation and 10-second prescription issuance, with 1,525 clinic membership stores currently using the system [3] - The AI-assisted diagnosis platform developed in collaboration with Tencent Cloud covers nearly 3,000 diseases and over 110,000 drug knowledge, with an average of 51,000 uses per month across member stores [3] - The new product strategy, as part of the "Three New and Two Transformations" strategy, is crucial for future development, focusing on integrating resources across the group to introduce clinically valuable and marketable new products [3] Group 4 - The company has established a new product strategy fund, "Wuhan Jiu Ying Venture Capital Fund Partnership," with a scale of 500 million yuan, focusing on innovative drugs and high-end generics [4]

Group 1 - The company held its 2025 semi-annual performance briefing on September 3, where executives reported steady progress in its new medical strategy, with over 2,400 clinic member stores established by the end of July 2025, aiming to achieve a network of 10,000 clinics within three years [1] Group 2 - The company's subsidiary, Jiuyi Clinics, focuses on a business model that integrates "medical services + supply chain," primarily based on supply chain operations, promoting products and forming a member alliance across clinics [2] - The company has introduced over 260 new products in the first half of the year, enhancing the product structure for clinics by collaborating with multiple upstream manufacturers, including Taiji, China Resources Sanjiu, Changfeng Pharmaceutical, Jilin Aodong, and Tianyao Pharmaceutical [2] - The company has developed and launched the Jiuyi SaaS Clinic Manager system, providing intelligent operational value-added services to clinic clients, enabling quick documentation and billing processes, with 1,525 clinic member stores currently using the system [2] - The company partnered with Tencent Cloud to develop the Jiuyi Clinic AI-assisted diagnosis platform, which integrates Tencent's medical AI reasoning, covering nearly 3,000 diseases and 110,000 drug knowledge, with an average of 51,000 monthly uses of the AI-assisted diagnosis platform across member stores [2]

Core Viewpoint - 九州通 has reported strong financial performance for the first half of 2025, achieving a revenue of 81.106 billion yuan, a year-on-year increase of 5.10%, and a net profit of 1.446 billion yuan, up 19.70%, despite industry challenges [1] Group 1: Financial Performance - The company achieved a revenue of 81.106 billion yuan in H1 2025, reflecting a 5.10% year-on-year growth [1] - The net profit attributable to shareholders reached 1.446 billion yuan, marking a 19.70% increase compared to the previous year [1] Group 2: Strategic Initiatives - 九州通 is focusing on its "Three New and Two Digital" strategy, which includes new products, new retail, new medical services, digitalization, and real estate securitization [2] - The company introduced 61 new pharmaceutical products during the reporting period, with total sales revenue from brand promotion reaching 9.591 billion yuan [2] Group 3: New Retail and Medical Services - The new retail strategy, centered around the "Good Medicine Master" franchise, generated sales revenue of 1.493 billion yuan, a 2.52% increase year-on-year [2] - The number of "Good Medicine Master" stores reached 31,535 by the end of June 2025, with expectations to exceed 33,500 by the end of the year [3] Group 4: Digitalization and AI Integration - 九州通 has developed a SaaS system for clinic management, enhancing operational efficiency with features like rapid patient registration and billing [4] - The company has partnered with Tencent Cloud to create an AI-assisted diagnostic platform, which is currently used in over 1,500 clinics [4] Group 5: Emerging Business Growth - The pharmaceutical manufacturing segment achieved sales of 1.593 billion yuan, a 10.77% increase, while the digital logistics segment reported revenue of 0.587 billion yuan, up 24.66% [7][8] - The medical beauty business generated sales of 0.583 billion yuan, reflecting a significant growth of 48.64% [8] Group 6: ESG and Credit Rating - 九州通 has committed to social responsibility, donating 11.3781 million yuan in the first half of 2025 and receiving various ESG ratings, including "AA" from mainstream ESG rating agencies [9] - The company achieved a AAA credit rating from a leading credit rating agency, marking it as the only AAA-rated private enterprise in the pharmaceutical distribution sector [9]